268 results
8-K
EX-99.1
BIIB
Biogen Inc
24 Apr 24
First quarter revenue $2.3 billion; GAAP diluted EPS $2.70; Non-GAAP diluted EPS $3.67
7:02am
litigation, as all are hard to predict, or any impact of potential tax or healthcare reform. Biogen may incur charges, realize gains or losses, or experience … associated with current and potential future healthcare reforms; risks related to commercialization of biosimilars; failure to obtain, protect
8-K
EX-99.1
j5cdbqeutbor6tner dm
13 Feb 24
Biogen reports fourth quarter and full year 2023 results and expects return to Non-GAAP EPS growth in 2024
7:07am
8-K
EX-99.1
po1d4 ap36t6libp
8 Nov 23
Biogen reports third quarter 2023 results and updates full year 2023 guidance
7:02am
8-K
d17y4f1a7radkq0lk2w
26 Sep 23
Biogen Completes Acquisition of Reata Pharmaceuticals
5:25pm
8-K
EX-99.1
2rfhw4ry6z
26 Sep 23
Biogen Completes Acquisition of Reata Pharmaceuticals
5:25pm
DEFA14A
en9tszmfe0vz ynd15e
31 Jul 23
Additional proxy soliciting materials
7:02am
8-K
45hhv
31 Jul 23
Entry into a Material Definitive Agreement
7:00am
DEFA14A
inas50
28 Jul 23
Additional proxy soliciting materials
7:13am
8-K
k7krfgapmexz3uf2z
28 Jul 23
Other Events
7:11am
8-K
EX-99.2
r5m48is15bc5ktd
28 Jul 23
Other Events
7:11am
8-K
EX-99.1
ixamy9bl39rgmq4
25 Jul 23
Second quarter revenue $2,456 million; GAAP diluted EPS $4.07; Non-GAAP diluted EPS $4.02
7:03am
DEFR14A
dqiojr3
13 Jun 23
Revised proxy
7:25am
DEFA14A
d0qoe xgpbqtk
12 Jun 23
Additional proxy soliciting materials
5:18pm